EcoDrugPlus

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSOMYG00000011773
Gene Symbol: CACNB1
1 Cross references
203 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSOMYG00000033616
Gene Symbol: CACNB1
1 Cross references
203 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3a

Ensembl ID : ENSOMYG00000036674
Gene Symbol: CACNB3A
1 Cross references
194 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 4a Subunit

Ensembl ID : ENSOMYG00000043021
Gene Symbol: CACNB4A
1 Cross references
198 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 4a Subunit

Ensembl ID : ENSOMYG00000001164
Gene Symbol: CACNB4A
1 Cross references
198 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 1a

Ensembl ID : ENSOMYG00000024964
Gene Symbol: CACNG1A
1 Cross references
188 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 1a

Ensembl ID : ENSOMYG00000039680
Gene Symbol: CACNG1A
1 Cross references
188 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 2a

Ensembl ID : ENSOMYG00000010554
Gene Symbol: CACNG2A
1 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 4b

Ensembl ID : ENSOMYG00000019283
Gene Symbol: CACNG4B
1 Cross references
188 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 4b

Ensembl ID : ENSOMYG00000059581
Gene Symbol: CACNG4B
1 Cross references
188 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 5b

Ensembl ID : ENSOMYG00000018218
Gene Symbol: CACNG5B
1 Cross references
168 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 5b

Ensembl ID : ENSOMYG00000066395
Gene Symbol: CACNG5B
1 Cross references
168 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).